Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377021 | 1.00 | HDAC4 (0.41) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL14415710 | 0.81 | AOC3 (0.41) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL5150149 | 0.81 | AOC3 (0.41) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL14415707 | 0.81 | AOC3 (0.41) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL24296569 | 0.80 | ACHE (0.45) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL97560 | 0.80 | CES2 (0.47) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL689304 | 0.79 | HDAC4 (0.42) | HDAC4CYP11B1CYP11B2 | |
| SCHEMBL8657495 | 0.79 | HDAC4 (0.43) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL3556521 | 0.78 | HDAC4 (0.42) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL6557765 | 0.78 | ALDH1A1 (0.47) | ACHEAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663960-B1 | AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2011-08-24 | — | — | EP | disclosed |
| US-7674806-B2 | Amidines and derivatives thereof and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20070155717-A1 | Amidines and derivatives thereof and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A (IT) | 2007-07-05 | — | — | US | disclosed |
| CN-1882530-A | Amidines and derivatives thereof and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG (IT) | 2006-12-20 | — | — | CN | disclosed |
| EP-1663960-A2 | AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028425-A2 | AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ PHA.R.MA S.P.A. (IT) | 2005-03-31 | — | — | WO | disclosed |
| CN-1153568-C | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | NPSҩ������˾ | 2004-06-16 | — | — | CN | disclosed |
| CN-1088585-C | Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases | NPS PHARMACEUTICAL CO LTD (US) | 2002-08-07 | — | — | CN | disclosed |
| EP-0912494-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998056752-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| CN-1192679-A | Compounds active at a novel side on receptor-operated calcium channel useful for treatment of neurological disorders | N P S PHARMACEUTICALS INC (US) | 1998-09-09 | — | — | CN | disclosed |
| WO-1997046511-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| CN-1148337-A | Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases | NPS PHARMACEUTICAL CO LTD (US) | 1997-04-23 | — | — | CN | disclosed |
| EP-0743853-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021612-A2 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155717-A1 | Amidines and derivatives thereof and pharmaceutical compositions containing them | MMP8, CXCL8, MPO | HDAC4 2904/4885HDAC7 1267/4885HDAC5 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.